Senores Pharmaceuticals Limited has announced its financial and operational highlights for the third quarter and the first nine months of FY26, alongside an update on its investor presentation.

The company reported robust cash flow from operations for Q3FY26 at approximately ₹19 crore and ₹51 crore for 9MFY26, showing significant year-over-year growth. EBITDA to operating cash flow conversion has improved.

Senores Pharmaceuticals highlighted a strong product pipeline for regulated markets, with 46 approved ANDAs covering 137 strengths, and an additional 22 ANDAs under development. The company also achieved its highest ever revenue and EBITDA from Emerging Markets, with revenue growing by approximately 48% year-on-year in Q3FY26 and EBITDA margins jumping to approximately 13% from 1% in Q3FY25.

An update on the acquisition of Apnar Pharmaceuticals indicates that Phase 1, involving a 75% stake acquisition, has been completed. Phase 2, for the remaining 25% stake, is expected to be completed by Q2FY27. Three approved ANDAs are slated for launch in Q4FY26, which are expected to generate positive cash flow. Business integration is progressing faster than anticipated.

Consolidated financial highlights for Q3 & 9M FY26 show a significant increase in Total Income, EBITDA, and PAT. Total Income grew by 64% to ₹174.6 crore in Q3FY26 and by 65% to ₹474.3 crore in 9MFY26. EBITDA increased by 86% to ₹54.0 crore in Q3FY26 and by 87% to ₹137.7 crore in 9MFY26. PAT saw a substantial rise of 105% to ₹33.6 crore in Q3FY26 and 110% to ₹84.9 crore in 9MFY26.

The company also provided an update on the utilization of funds from its IPO, with ₹362.1 crore utilized out of ₹500.0 crore as of December 31, 2025. The largest unutilized amount is for investment in a subsidiary to fund capital expenditure for a manufacturing facility.

Further details on the Apnar Pharma acquisition reveal a total enterprise value of approximately ₹91 crore. The first tranche of 75% stake acquisition was completed in January 2026 for approximately ₹11.5 crore, with the remaining 25% to be acquired by Q2FY27. The acquisition is expected to provide immediate access to regulated markets, enhance R&D capabilities, and offer revenue and cost synergies.

Senores Pharmaceuticals Limited operates in Regulated Markets, Emerging Markets, API, and Branded Generics businesses, with a strong focus on R&D and a robust regulatory track record, including USFDA approvals for its facilities.